PDF(Pubmed)
Abstract：
BACKGROUND: Evaluation of anterior segment parameters is crucial in ophthalmic procedures such as intraocular surgeries and contact lens fitting. However, the use of tropicamide in diabetic patients presents challenges due to its potential impact on biometric measurements. This study aims to investigate and compare the effects of 0.5% and 1% tropicamide on anterior segment parameters in diabetic patients.
METHODS: This double-masked randomized clinical trial enrolled 98 patients with diabetes mellitus. Participants were randomly assigned to receive either 0.5% or 1% tropicamide. Anterior segment parameters were measured using Pentacam HR (Oculus Optikgeräte GmbH, Wetzlar, Germany) before and 30 minutes after tropicamide administration. Parameters included anterior chamber depth (ACD), anterior chamber volume (ACV), anterior chamber angle (ACA), keratometry, central corneal thickness (CCT), white-to-white distance (WTW), and pupillary diameter (PD).
RESULTS: Both concentrations of 0.5% and 1% tropicamide induced significant changes in anterior segment parameters. There was a notable increase in PD (2.99 ± 0.62, 3.11 ± 0.55, respectively, both P-values < 0.001), ACD (both 0.10 ± 0.05, both P-values < 0.001), ACV (16.69 ± 9.56, 17.51 ± 9.26, respectively, both P-values < 0.001), and WTW (0.06 ± 0.14, 0.03 ± 0.30, respectively, both P-values < 0.001), along with a decrease in ACA (-3.50 ± 10.65, -3.30 ± 6.87, P-value < 0.001 and P-value=0.001, respectively), and CCT (-6.10 ± 8.06, -6.39 ± 9.97, respectively, both P-values < 0.001) post-dilation. However, no significant changes were observed in keratometry (front Km (-0.03 ± 0.19, -0.04 ± 0.21, respectively), back Km (0.01 ± 0.05, 0.004 ± 0.05, respectively), P-values> 0.05).
CONCLUSIONS: Both concentrations of tropicamide exhibited comparable effects on anterior segment parameters in diabetic patients. These post-dilation changes should be considered for accurate intraocular lens power calculation and decision-making for cataract, phakic intraocular lens, and refractive surgeries.
METHODS: This double-masked randomized clinical trial enrolled 98 patients with diabetes mellitus. Participants were randomly assigned to receive either 0.5% or 1% tropicamide. Anterior segment parameters were measured using Pentacam HR (Oculus Optikgeräte GmbH, Wetzlar, Germany) before and 30 minutes after tropicamide administration. Parameters included anterior chamber depth (ACD), anterior chamber volume (ACV), anterior chamber angle (ACA), keratometry, central corneal thickness (CCT), white-to-white distance (WTW), and pupillary diameter (PD).
RESULTS: Both concentrations of 0.5% and 1% tropicamide induced significant changes in anterior segment parameters. There was a notable increase in PD (2.99 ± 0.62, 3.11 ± 0.55, respectively, both P-values < 0.001), ACD (both 0.10 ± 0.05, both P-values < 0.001), ACV (16.69 ± 9.56, 17.51 ± 9.26, respectively, both P-values < 0.001), and WTW (0.06 ± 0.14, 0.03 ± 0.30, respectively, both P-values < 0.001), along with a decrease in ACA (-3.50 ± 10.65, -3.30 ± 6.87, P-value < 0.001 and P-value=0.001, respectively), and CCT (-6.10 ± 8.06, -6.39 ± 9.97, respectively, both P-values < 0.001) post-dilation. However, no significant changes were observed in keratometry (front Km (-0.03 ± 0.19, -0.04 ± 0.21, respectively), back Km (0.01 ± 0.05, 0.004 ± 0.05, respectively), P-values> 0.05).
CONCLUSIONS: Both concentrations of tropicamide exhibited comparable effects on anterior segment parameters in diabetic patients. These post-dilation changes should be considered for accurate intraocular lens power calculation and decision-making for cataract, phakic intraocular lens, and refractive surgeries.
摘要：
背景：眼前节参数的评估在眼科手术如眼内手术和隐形眼镜试镜中至关重要。然而,在糖尿病患者中使用托吡卡胺面临挑战,因为其对生物特征测量的潜在影响.这项研究旨在调查和比较0.5％和1％的托吡卡胺对糖尿病患者眼前节参数的影响。
方法：这项双盲随机临床试验纳入了98名糖尿病患者。参与者被随机分配接受0.5%或1%的托吡卡胺。使用PentacamHR（OculusOptikgeräteGmbH，Wetzlar,德国）在给予托吡卡胺之前和之后30分钟。参数包括前房深度（ACD），前房容积（ACV），前房角(ACA),角膜曲率测量,中央角膜厚度(CCT),白到白距离(WTW),和瞳孔直径（PD）。
结果：浓度为0.5％和1％的托吡卡胺均引起眼前节参数的显着变化。PD显着增加（分别为2.99±0.62，3.11±0.55，两个P值<0.001)，ACD（均为0.10±0.05，均P值<0.001），ACV（分别为16.69±9.56，17.51±9.26，两个P值<0.001)，和WTW(分别为0.06±0.14、0.03±0.30，两个P值<0.001)，随着ACA的减少（分别为-3.50±10.65，-3.30±6.87，P值<0.001和P值=0.001），和CCT(分别为-6.10±8.06，-6.39±9.97，两个P值<0.001)扩张后。然而,角膜曲率测量无明显变化（前Km（分别为-0.03±0.19，-0.04±0.21），回Km（分别为0.01±0.05，0.004±0.05），P值>0.05)。
结论：两种浓度的托吡卡胺对糖尿病患者的眼前节参数具有相当的影响。这些扩张后的变化应被考虑，以准确的人工晶状体屈光力计算和白内障的决策，有晶状体眼人工晶状体,和屈光手术。
方法：这项双盲随机临床试验纳入了98名糖尿病患者。参与者被随机分配接受0.5%或1%的托吡卡胺。使用PentacamHR（OculusOptikgeräteGmbH，Wetzlar,德国）在给予托吡卡胺之前和之后30分钟。参数包括前房深度（ACD），前房容积（ACV），前房角(ACA),角膜曲率测量,中央角膜厚度(CCT),白到白距离(WTW),和瞳孔直径（PD）。
结果：浓度为0.5％和1％的托吡卡胺均引起眼前节参数的显着变化。PD显着增加（分别为2.99±0.62，3.11±0.55，两个P值<0.001)，ACD（均为0.10±0.05，均P值<0.001），ACV（分别为16.69±9.56，17.51±9.26，两个P值<0.001)，和WTW(分别为0.06±0.14、0.03±0.30，两个P值<0.001)，随着ACA的减少（分别为-3.50±10.65，-3.30±6.87，P值<0.001和P值=0.001），和CCT(分别为-6.10±8.06，-6.39±9.97，两个P值<0.001)扩张后。然而,角膜曲率测量无明显变化（前Km（分别为-0.03±0.19，-0.04±0.21），回Km（分别为0.01±0.05，0.004±0.05），P值>0.05)。
结论：两种浓度的托吡卡胺对糖尿病患者的眼前节参数具有相当的影响。这些扩张后的变化应被考虑，以准确的人工晶状体屈光力计算和白内障的决策，有晶状体眼人工晶状体,和屈光手术。
